DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1020548
Title:
Investigating the Regulation and Potential Role of Nonhypoxic Hypoxia Inducible Factor 1 (HIF 1) in Aromatase Inhibitor Resistant Breast Cancer
Descriptive Note:
Technical Report,15 Sep 2011,14 Sep 2015
Corporate Author:
University of Maryland, Baltimore Baltimore United States
Report Date:
2015-12-01
Pagination or Media Count:
75.0
Abstract:
This research aims to understand the factors and molecular mechanisms involved in drug-resistant breast cancer, specifically aromatase inhibitor resistant breast cancer. Although aromatase inhibitors AIs i.e., letrozole have been shown to be highly effective in treating estrogen receptor positive ER breast cancer, a significant percentage of patients either do not respond to AIs or become resistant to them. Previous studies suggest that resistance to AIs involves a switch from dependence on ER signaling to dependence on growth factor-mediated pathways, such as human epidermal growth factor receptor-2 HER2. The mechanism by which HER2 is involved in AI resistance remains mostly unclear. It is, therefore, important to elucidate theHER2-mediated pathway that contributes to AI resistance, and to identify other relevant factors involved that can be used as biomarkers of AI resistance or targets for therapy.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
